Panacea Biotec Limited has informed the Exchange regarding a press release dated Jun 03, 2025, titled "Press Release - Inclusion of EmulsiPan adjuvant in the CEPI Adjuvant Library and its foray into commercialisation of its indigenously developed adjuvants".
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Panacea Biotec announced that its in-house developed adjuvant 'EmulsiPan' has been included in the CEPI (Coalition for Epidemic Preparedness Innovations) Adjuvant Library, an international platform that supports vaccine and biotherapeutic research. EmulsiPan is an oil-in-water emulsion adjuvant originally developed in 2009 and used in the company's H1N1 vaccine PandyFlu. The product has been used in preclinical studies including COVID-related vaccine work with Caltech and India's THSTI. The company is now commercialising the adjuvant on an open-access, royalty-free basis for vaccine developers globally, with no licensing fees. The global adjuvant market is estimated to cross $4.8 billion by 2028, providing context for the commercial opportunity. The company has over 1,500 global patents and a track record in polio and combination vaccines.
This is a scientific validation and a soft entry into a niche but growing global market rather than a confirmed order or revenue trigger. Positively, it opens a new, asset-light revenue stream through adjuvant sales, but near-term impact on the stock is likely to be limited as commercial scale-up and demand will take time to materialise.